Browsing by Author "Nankya Mutyoba, Joan"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Corrigendum to “Hepatitis B birth dose vaccination for newborns in Uganda: A qualitative inquiry on pregnant women’s perceptions, barriers and preferences”
    (Journal of Virus Eradication, 2021) Nankya Mutyoba, Joan; Surkan, Pamela J.; Makumbi, Fredrick; Aizire, Jim; Kirk, Gregory D.; Ocama, Ponsiano; Atuyambe, Lynn M.
    The full acknowledgment for the article is restated herein: This research (or [initials]) was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No—G-19-57145), Sida (Grant No:54100113), Uppsala Monitoring Center and the DELTAS Africa Initiative (Grant No: 107768/Z/ 15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow.
  • Thumbnail Image
    Item
    Integrating Hepatitis B Care and Treatment with Existing HIV Services is Possible: A Cost Minimization Analysis from a Low Resource Setting
    (Research Square, 2020) Ejalu, David Livingstone; Nankya Mutyoba, Joan; Wandera, Claude; Seremba, Emmanuel; Kambugu, Andrew; Easterbrook, Philippa; Amandua, Jacinto; Muganzi, Alex; Rachel, Beyagira; Mugagga, Kaggwa; Ocama, Ponsiano
    In recent years there has been growing interest in exploring methods by which the care pathways for people with comorbid physical and health problems may be integrated. The success of such an integration however would depend on several factors including feasibility, acceptability and costs involved. Therefore, this report presents estimated provider costs associated with managing an integrated HBV and HIV clinical pathway for patients on life-long treatment in low resource setting in Uganda. Methods: A cost minimisation analysis from the providers perspective was done by considering financial costs as a measure of the amount of money spent on resources used in the clinical pathways. The annual cost per patient was simulated based on total amount of resources spent for all the patient visits to the facility for HBV or HIV care per year. Results: Findings showed that drugs and laboratory tests were the main drivers of costs in the pathways. A high-volume facility (Arua regional referral hospital- ARRH) had a higher cost per patient in both clinics than did the low volume facility (Koboko District Hospital- KDH). Variations occurred due to differences in the carders of health workers, the infrastructure, the amounts of consumables used in the facilities. Cost per HBV patient was $163.59 in ARRH and $145.76 in K DH while the cost per HIV patient was $176.52 in ARRH and $173.23 in KDH. The integration resulted into total saving of $36.73 per patient per year in Arua RRH and $17.5 in Koboko DH. The cost saving accrued from savings from personnel, fixed costs, consumables and utilities incurred in running the standalone Hepatitis B clinic and the reduction in per HIV patient costs from sharing of resources in the integrated pathway. Conclusion: This analysis showed that the application of the integrated Pathway in HIV and HBV patient management could improve hospital cost efficiency compared to operating stand-alone clinics. This could further improve adherence to treatment by Hepatitis B patients and improve patient outcomes as HBV patients get access to counselling services.